Johnson & Johnson will go head-to-head in the US neurovascular market against Medtronic PLC and Stryker Corp. with its EmboTrap clot retrieval device, after US FDA gave the product the thumbs-up.
The device, which is already CE-marked, received 510(k) clearance on May 9. It will be commercialized by J&J's Cerenovus division...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?